Bayer HealthCare AG is subsidiary of Bayer AG group, which has three major sub-groups-Bayer HealthCare, Bayer CropScience and Bayer Material Science. Bayer HealthCare AG has further four divisions – Animal Health, Consumer Care, Medical Care and Pharmaceuticals. Pharmaceutical Division is the largest entity of Bayer HealthCare and is known as Bayer Pharma AG and employs nearly 38000 employees worldwide and contributes to approx. €11 billion in annual revenue.
Bayer AG is a Global Life Science company with a more than 150-year history and core competencies in the areas of health care and agriculture. Since 2003, Bayer AG acts as a holding company of Bayer Group of companies.
- In Sep 2019, cancer drug Vitrakvi™ (Larotrectinib) becomes the first-ever tumor-agnostic treatment to be approved in Europe. Vitrakvi™ targets specific genetic mutations found across completely different types of cancer. It can therefore be used to treat different types of tumor.
- In 2019, an oral androgen receptor inhibitor (ARi) NUBEQA® (darolutamide) was approved in the U.S. for the treatment of patients with non-metastatic castration-resistant prostate cancer (nmCRPC). Darolutamide is jointly developed by Bayer and Orion Corp.
- In Sep 2017, U.S. FDA granted accelerated approval to Aliqopa (copanlisib) for the treatment of adults with relapsed follicular lymphoma who have received at least two prior treatments known as systemic therapies.
- In 2015, Stivarga® (Regorafenib), an oral multi-kinase inhibitor, which targets angiogenic, stromal and oncogenic receptor tyrosine kinase (RTK) is US FDA approved for hepatocellular carcinoma in people who have been previously treated with sorafenib.
- On Feb 2013, FDA and MHLW (in Japan) approved Stivarga® to treat patients with locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate.
- Earlier, FDA (2012) and EMEA (2013) both approved Regorafenib/Stivarga® for the treatment of patients with mCRC who have been previously treated with fluropyrimidine, oxaliplatin and irinotecan based chemotherapy.
- Sorafenib tosylate/Nexavar®, FDA approved for renal cell carcinoma and hepatocellular carcinoma, is co-developed and co-marketed by Bayer and Onyx.
- On Nov 2013, FDA also approved Nexavar® for the treatment of patients with locally recurrent or metastatic, progressive, differentiated thyroid carcinoma that is refractory to radioactive iodine (RAI) treatment.
- In May 2013, Algeta lead candidate Xofigo®/Alpharadin® obtained FDA for the treatment of patients with castration-resistant prostate cancer (CRPC), symptomatic bone metastases and no known visceral metastatic disease. Bayer’s Xofigo® / Radium-223 dichloride, is a first-in-class alpha particle-emitting radiopharmaceutical that has been approved for CRPC.
Page 1 of 2
